<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Cardinal Health</title>
	<atom:link href="http://www.stockbloghub.com/tag/cardinal-health/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CAH) Cardinal Health Gets Antitrust Clearance</title>
		<link>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814</link>
		<comments>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814#comments</comments>
		<pubDate>Mon, 20 Dec 2010 20:27:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62814</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced that antitrust regulators had cleared its $1.3 billion takeover of Kinray, a leading pharma distributor with a presence in the New York metropolitan area. In this regard, the Federal Trade Commission (“FTC”) had approved early termination of waiting period, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, for the planned takeover. The cash deal to acquire Kinray will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to shortly close the deal. The company earlier anticipated that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Announces Buy of Kinray</title>
		<link>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379</link>
		<comments>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:25:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60379</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced plans to purchase Kinray Inc., a leading pharma distributor with a presence in the New York metropolitan area. The cash deal will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to close the deal by the end of the current calendar year, or early-2011, depending on regulatory approval and closing conditions. The company anticipates that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal 2012, after taking into account the effect of amortization of intangibles. Kinray is one of the largest privately held distributors of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Prepares for Coming Flu Season</title>
		<link>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709</link>
		<comments>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:13:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53709</guid>
		<description><![CDATA[Cardinal Health (CAH) is taking necessary steps to maintain the supply of influenza vaccines during the forthcoming 2010-2011 flu season. For the first time, the Advisory Committee on Immunization Practices (ACIP) has been asking everyone over 6 months of age to get a flu vaccine. The company is of the opinion that the supplies are sufficient to meet the demand as a result of which everybody will have access to the vaccine. There is no need of prioritization. The flu season of last year resulted in more than 270,000 hospitalizations and 12,000 deaths. However, the upcoming season should not be very severe due to the immunity developed from the last infection and availability of the flu vaccine. Moreover, the flu vaccine will target the H1N1 strain in addition to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Sells Remaining CareFusion Shares</title>
		<link>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054</link>
		<comments>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054#comments</comments>
		<pubDate>Sun, 19 Sep 2010 17:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52054</guid>
		<description><![CDATA[Cardinal Health (CAH), a leading distributor of pharmaceuticals and medical supplies, recently sold off the remaining 30.5 million shares of CareFusion Corporation (CFN) for $705.9 million. CareFusion, a San Diego-based vendor for medical equipment and infection control supplies, was spun off from Cardinal Health in 2009. As per the spin-off arrangement, Cardinal Health distributed 0.5 shares of CareFusion common stock for each share of its stock that was outstanding. It retained about 19% of the shares in CareFusion at the time of the distribution. Under the terms of the agreement Cardinal Health was required to dispose of its equity holdings in CareFusion within five years of the distribution (by August 31, 2014). The agreement authorized Cardinal to dispose of its shares through open-market sales, private sales or a combination of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444</link>
		<comments>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:15:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48444</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250</link>
		<comments>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48250</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655</link>
		<comments>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655#comments</comments>
		<pubDate>Thu, 12 Aug 2010 05:16:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47655</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, recently reported earnings for fourth-quarter of fiscal year 2010, which beat the Zacks Consensus Estimate by a penny. Revenues grew by a mere 0.5% year over year to $22.3 billion. Pharmaceutical revenues were essentially flat year over year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. The spin-off of CareFusion (CFN) has enabled Cardinal to increase focus on its core healthcare supply chain business. Moreover, Cardinal recently acquired privately held specialty pharmaceutical services company Healthcare Solutions Holding for $667 million. The acquisition has expanded its foothold in the fast-growing specialty pharmaceutical services segment. Agreement – ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Reaffirms Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468</link>
		<comments>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468#comments</comments>
		<pubDate>Wed, 11 Aug 2010 01:34:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47468</guid>
		<description><![CDATA[We maintain our Neutral recommendation for Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies. Earnings for fourth-quarter fiscal 2010 beat the Zacks Consensus Estimate by a penny. However, profit dipped year-over-year, impacted by the spin-off of the company’s non-core Clinical and Medical Products segment (CareFusion), lower customer pricing and supply disruption in the pharmaceutical segment. Revenues grew by a mere 0.5% year-over-year to $22.3 billion, narrowly missing the Zacks Consensus Estimate. Pharmaceutical revenues were essentially flat year-over-year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. Cardinal is one of the largest global healthcare companies that help pharmacies, hospitals and ambulatory care sites to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health&#8217;s Report Beats Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854</link>
		<comments>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854#comments</comments>
		<pubDate>Fri, 06 Aug 2010 16:56:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46854</guid>
		<description><![CDATA[Cardinal Health (CAH) reported fourth-quarter and fiscal 2010 adjusted (excluding one-time expenses) earnings per share of 50 cents and $2.22 respectively, exceeding the Zacks Consensus Estimates of 49 cents and $2.21, respectively, but below the year-ago results of 63 cents and $2.26, respectively. Revenues Total revenue was $24.5 billion in the fourth quarter, up by a mere 0.5% year over year, and $98.5 billion in fiscal 2010, up 3%. Reported results were marginally below the Zacks Consensus Estimates of $24.6 billion and $98.7 billion for the fourth quarter and fiscal year, respectively. Segment-wise Revenue The Pharmaceutical segment reported fourth-quarter revenue of $22.3 billion, up a nominal 0.2%. Sales to non-bulk customers were $11.5 billion, up 3% year over year, while sales to bulk customers were $10.8 billion, down 3%. Generic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/cah-cardinal-healths-report-beats-expectations-by-a-penny/46854/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health &#8211; Increased Dividend by 11%</title>
		<link>http://www.stockbloghub.com/2010/08/06/cah-cardinal-health-increased-dividend-by-11/46918</link>
		<comments>http://www.stockbloghub.com/2010/08/06/cah-cardinal-health-increased-dividend-by-11/46918#comments</comments>
		<pubDate>Fri, 06 Aug 2010 16:49:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46918</guid>
		<description><![CDATA[Cardinal Health (CAH) is in a stable industry with steady revenues and a safe dividend. Growth and Income The company is expected to grow its EPS 10.8% over the next three to five years. The stock also offers investors a dividend yield of 2.3%. This Zacks #2 Rank stock trades at 13.4x fiscal year 2011 consensus EPS estimates. Business Cardinal Health provides health care products and services primarily in the US. Its largest segment distributes branded and private-label pharmaceuticals to retail customers, hospitals, and alternate care providers. Fiscal Fourth-Quarter Results On August 5, Cardinal reported financial results for the fourth quarter of fiscal year 2010. Cardinal&#8217;s revenue rose 0.5% to $24.5 billion from $24.3 billion in the year-ago quarter. The company earned $0.50 per share, beating the Zacks Consensus Estimate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/cah-cardinal-health-increased-dividend-by-11/46918/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047</link>
		<comments>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047#comments</comments>
		<pubDate>Tue, 03 Aug 2010 04:23:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46047</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report fourth-quarter and fiscal 2010 (ending June 30, 2010) results on Thursday, August 5, 2010. The company earlier issued earnings per share guidance in the range of $2.15 to $2.20 for fiscal 2010. The current Zacks Consensus Estimate for the fourth quarter is 49 cents, representing an estimated 43.2% year over year decline. Third Quarter Recap Cardinal Health reported third-quarter fiscal 2010 adjusted (excluding one-time gain on sale of CareFusion stock) earnings per share of 61 cents, outperforming the Zacks Consensus Estimate of 57 cents. Total sales increased 1% year over year to $24.3 billion. The company experienced moderate growth in both its business segments, Pharmaceutical (comprising bulk and non bulk customers) and Medical. Revenues for the much larger Pharmaceutical segment increased 0.5% year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/cah-cardinal-health-earnings-preview/46047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Quarterly Earnings Outperform</title>
		<link>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762</link>
		<comments>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762#comments</comments>
		<pubDate>Fri, 30 Apr 2010 15:52:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35762</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported third quarter fiscal 2010 earnings per share of 61 cents, outperforming the Zacks Consensus Estimate of 57 cents. However, earnings were lower than the year-ago figure of 66 cents. Sales Total sales in the third quarter increased 1% year over year to $24.3 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 0.5% year over year to $22.2 billion. Growth was fueled by higher sales to bulk and non-bulk customers. Sales to bulk customers increased 0.5% year over year to $10.9 billion. Sales to non-bulk customers increased 0.5% year over year to $11.3 billion. Medical segment revenues increased 7% year over year to $2.1 billion. Growth can be primarily attributed to higher sales to existing domestic customers and strong performance of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Beats Forecasts &#8211; Raises Outlook Again</title>
		<link>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742</link>
		<comments>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742#comments</comments>
		<pubDate>Thu, 22 Apr 2010 21:32:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34742</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) posted second quarter fiscal 2010 earnings of 63 cents per share, beating the Zacks Consensus Estimate by 8 cents. Earnings increased 34% from the year-ago period. Performance was driven by strong revenues, successful generic drug launches, and continued expense management. Total revenues for the quarter increased 11.5% to $19.3 billion. This was attributable to a 13% growth in AmerisourceBergen Drug Corp. revenues and a 5% rise in Specialty Group revenues. AmerisourceBergen Drug Corp. revenues were driven by new customer additions and overall market growth. New business accounted for more than 4% of revenue growth. Meanwhile, generic revenues remained strong during the quarter. Gross profit for the second quarter was $612.1 million, which reflected an 11% increase over the year-ago period. The improvement was driven by increased revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Decides to Acquire Medegen for $225 Million</title>
		<link>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028</link>
		<comments>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028#comments</comments>
		<pubDate>Thu, 08 Apr 2010 00:24:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33028</guid>
		<description><![CDATA[CareFusion Corporation (CFN) has decided to acquire Medegen for $225 million in cash. CareFusion expects the acquisition to be neutral to the adjusted earnings per share in the first year of operations and increasingly accretive thereafter. The acquisition is expected to be completed by June 30, 2010. Medegen is a leading innovator in infusion therapy which consists of clinically differentiated needle-less access valves and administration sets that deliver intravenous (IV) medication to patients. We believe Medegen would be a ‘strategic fit’ for CareFusion and it will be able to fully integrate Medegen’s operations. Both CareFusion and Medegen have matching infusion product lines and R&#38;D investments. Furthermore, CareFusion’s products are also backed by clinical evidence and differentiation. CareFusion is a medical technology company formed by the spin-off of the Clinical and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PBR) U.S. Consumer Price Index Remains Tame</title>
		<link>http://www.stockbloghub.com/2010/03/18/pbr-u-s-consumer-price-index-remains-tame/31205</link>
		<comments>http://www.stockbloghub.com/2010/03/18/pbr-u-s-consumer-price-index-remains-tame/31205#comments</comments>
		<pubDate>Thu, 18 Mar 2010 20:26:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Oil & Gas Drilling & Exploration]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[APA]]></category>
		<category><![CDATA[Apache Corporation]]></category>
		<category><![CDATA[ATP Oil & Gas Corporation]]></category>
		<category><![CDATA[ATPG]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[inflation]]></category>
		<category><![CDATA[PBR]]></category>
		<category><![CDATA[Petroleo Brasileiro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31205</guid>
		<description><![CDATA[We got more evidence today that inflation is not a serious concern. The Consumer Price Index (CPI) was unchanged in February after five straight months when it had increased by only 0.2% per month. Overall consumer prices are just 2.1% higher than a year ago. If food and energy prices are stripped out to get “core&#8221; inflation, then inflation is also very tame, with core inflation up 0.1% in February, reversing a 0.1% decline in January and a 0.1% increase in December. Over the last year, core inflation has just been 1.3%, and most of that inflation happened earlier in 2009. Actually, food prices have been very well behaved, down 0.2% over the last year, but up slightly (0.1%, 0.2%, and 0.1%) in each of the last three months. Energy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/pbr-u-s-consumer-price-index-remains-tame/31205/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health &#8211; Earnings Estimates Are Moving Higher</title>
		<link>http://www.stockbloghub.com/2010/03/03/cah-cardinal-health-earnings-estimates-are-moving-higher/29442</link>
		<comments>http://www.stockbloghub.com/2010/03/03/cah-cardinal-health-earnings-estimates-are-moving-higher/29442#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:51:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29442</guid>
		<description><![CDATA[Cardinal Health (CAH) provides investors with 10% earnings growth and a dividend yield of 2%. Company Description Cardinal Health is one of the largest distributors of pharmaceuticals and medical supplies. The company is also a leading provider of products and services that improve the safety and productivity of health-care providers. Cardinal Health manufactures medication infusion and dispensing products, respiratory equipment, and surgical instruments. Stable Business with Growth Potential The company&#8217;s diversified product portfolio generates a steady revenue stream even during economic downturns. Cardinal&#8217;s generic business should remain its fastest growing segment. The company has been expanding relationships with generic manufacturers. These relationships have several benefits including higher levels of service, greater clarity on costs, and more consistent product supply with fewer disruptions. Cardinal management expects its generic business to gain ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/cah-cardinal-health-earnings-estimates-are-moving-higher/29442/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655</link>
		<comments>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655#comments</comments>
		<pubDate>Thu, 11 Feb 2010 00:21:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27655</guid>
		<description><![CDATA[CareFusion Corporation (CFN) recently reported second quarter fiscal 2010 earnings per share of 39 cents, marginally beating the Zacks Consensus Estimate of 38 cents, but lower than the year-ago earnings of 50 cents. Total revenues in the second quarter increased 5% year over year to $1.0 billion. Growth was witnessed across all business segments. Critical Care Technologies revenues increased 1% year over year to $682 million as a result of higher demand for the company’s respiratory business. Medical Technologies and Services revenues increased 15% year over year to $337 million. Growth was driven by higher sales from the company’s International Surgical Products and Interventional Specialties businesses. CareFusion reported a contraction in margins in the second quarter. Adjusted gross margin declined 200 basis points (bps) year over year to 46.9%. Adjusted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Upgraded to Outperform</title>
		<link>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680</link>
		<comments>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680#comments</comments>
		<pubDate>Wed, 10 Feb 2010 21:17:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27680</guid>
		<description><![CDATA[We have recently upgraded Cardinal Health Inc. (CAH) to “Outperform&#8221; with a target price of $37 based on approximately 15.7x our fiscal 2011 EPS estimate of $2.36. Cardinal Health reported second quarter fiscal 2010 earnings per share of 57 cents, beating the Zacks Consensus Estimate of 46 cents and the year-ago earnings of 51 cents. Total sales increased 3% year over year to $24.9 billion, fueled by growth across all business segments. Pharmaceutical segment revenues increased 3% year over year to $22.7 billion. Growth was primarily fueled by higher sales to existing pharmaceutical distribution customers. Sales to bulk customers declined 1% year over year to $11.0 billion. Sales to non-bulk customers increased 7% year over year to $11.7 billion. Medical segment revenues increased 9% year over year to $2.2 billion. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/cah-cardinal-health-upgraded-to-outperform/27680/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Beats Expectations and Boosts Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312</link>
		<comments>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:26:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26312</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported second quarter fiscal 2010 earnings per share of 57 cents, surpassing the Zacks Consensus Estimate of 46 cents and the year-ago earnings of 51 cents. Sales Total sales in the reported quarter increased 3% year over year to $24.9 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 3% year over year to $22.7 billion. Growth was primarily fueled by higher sales to existing pharmaceutical distribution customers. Sales to bulk customers declined 1% year over year to $11 billion. Sales to non-bulk customers increased 7% year over year to $11.7 billion. Medical segment revenues increased 9% year over year to $2.2 billion. Growth can be primarily attributed to higher sales to existing customers. Margins Gross and operating margins remained unchanged at 3.8% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Eclipses Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/08/cah-cardinal-health-eclipses-consensus-estimates/19824</link>
		<comments>http://www.stockbloghub.com/2009/11/08/cah-cardinal-health-eclipses-consensus-estimates/19824#comments</comments>
		<pubDate>Mon, 09 Nov 2009 03:29:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19824</guid>
		<description><![CDATA[Cardinal Health (CAH) reported fiscal first-quarter earnings per share of 54 cents, surpassing the Zacks Consensus Estimate of 43 cents and the year-ago earnings of 47 cents. Sales Total sales in the reported quarter increased 6% year over year to $24.8 billion. Growth was witnessed across all the business segments. Pharmaceutical segment revenues increased 5% year over year to $22.6 billion. Growth was primarily due to higher sales to existing pharmaceutical distribution customers. Sales to bulk customers increased 6% year over year to $11.3 billion. Sales to non-bulk customers increased 5% year over year to $11.2 billion. Medical segment revenues increased 10% year over year to $2.2 billion. Growth can be primarily attributed to higher sales to existing customers. In addition, the CareFusion Corp. (CFN) spin-off has resulted in immediate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/cah-cardinal-health-eclipses-consensus-estimates/19824/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Completes Spin-Off &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/09/02/cah-cardinal-health-completes-spin-off-analyst-blog/14268</link>
		<comments>http://www.stockbloghub.com/2009/09/02/cah-cardinal-health-completes-spin-off-analyst-blog/14268#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:49:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14268</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) has completed the spin-off of its Clinical and Medical Products business to form a subsidiary, CareFusion Corporation (CFN). The spin-off was completed through a pro rata distribution of roughly 81% of CareFusion’s common stock. Roughly 222 million shares of CareFusion common stock were outstanding on the date of distribution. Of this, 180 million shares (81%) were distributed to Cardinal Health shareholders on a pro rata basis. Cardinal Health retained the balance 41 million shares, which will be divested within the next five years. Cardinal Health shareholders received 0.5 share of CareFusion common stock for each share of Cardinal Health they hold. We think that the spin-off will help Cardinal Health unlock the value of the assets tied to CareFusion and concentrate more on its core Healthcare ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/cah-cardinal-health-completes-spin-off-analyst-blog/14268/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Makes Buyback Offer</title>
		<link>http://www.stockbloghub.com/2009/08/28/cah-cardinal-health-makes-buyback-offer/13829</link>
		<comments>http://www.stockbloghub.com/2009/08/28/cah-cardinal-health-makes-buyback-offer/13829#comments</comments>
		<pubDate>Sat, 29 Aug 2009 00:08:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13829</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) has offered to buy back $1.2 billion of its long-term debt securities (notes) as part of its plan to reduce long-term debt after spinning off its CareFusion Corporation division on Aug 31, 2009. These securities carry maturity dates from 2011 to 2026. The offer expires on Sept. 24 and the owners of these securities must tender their notes by Sept 10 to receive the early tender premium. The notes were issued by Cardinal Health and its subsidiary, Allegiance Corp., Cardinal will finance the buyback with a combination of both cash in hand and a $1.4 billion it is expecting to generate from the CareFusion spin-off. The amount remaining after financing the tender offer will be used for retiring notes due in Oct 2009. We view the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/cah-cardinal-health-makes-buyback-offer/13829/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Sees Positive Results for Skin Preparation Drug</title>
		<link>http://www.stockbloghub.com/2009/08/27/cah-cardinal-health-sees-positive-results-for-skin-preparation-drug/13621</link>
		<comments>http://www.stockbloghub.com/2009/08/27/cah-cardinal-health-sees-positive-results-for-skin-preparation-drug/13621#comments</comments>
		<pubDate>Thu, 27 Aug 2009 18:57:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13621</guid>
		<description><![CDATA[Cardinal Health Inc. (CAH) announced that the use of the preoperative skin preparation, ChloraPrep, is significantly more effective than both DuraPrep and povidone-iodine at eliminating overall bacteria from the shoulder region. After antisepsis with ChloraPrep, only 7% of skin cultures tested positive for bacteria compared to 19% for DuraPrep and 31% for povidone-iodine. The data was published by The Journal of Bone and Joint Surgery recently. ChloraPrep is a product of Cardinal Health’s subsidiary, CareFusion, which the company will spin-off with effect from Aug 31. ChloraPrep is a preoperative skin preparation that reduces bacteria and other microorganisms on the patients&#8217; skin before any medical and surgical procedures. The drug remains effective for at least 48 hours after its application and reduces the risk of dangerous bloodstream and surgical site infections. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/cah-cardinal-health-sees-positive-results-for-skin-preparation-drug/13621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal&#8217;s Spin-off to be Added to S&amp;P 500 Index</title>
		<link>http://www.stockbloghub.com/2009/08/25/cah-cardinals-spin-off-to-be-added-to-sp-500-index/13360</link>
		<comments>http://www.stockbloghub.com/2009/08/25/cah-cardinals-spin-off-to-be-added-to-sp-500-index/13360#comments</comments>
		<pubDate>Tue, 25 Aug 2009 20:22:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Manitowoc Company Inc.]]></category>
		<category><![CDATA[MTW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13360</guid>
		<description><![CDATA[Cardinal Health Inc. (CAH) announced that its spin-off subsidiary, CareFusion Corp., will be included in the S&#38;P 500 after the close of trading on Aug 31. CareFusion replaces The Manitowoc Co. Inc. (MTW) in the index and will be added to the S&#38;P 500 GICS (Global Industry Classification Standard) Health Care Equipment Sub-Industry index. CareFusion is being formed by spinning off the Clinical and Medical Products business of Cardinal Health. The spin-off is expected to be completed on Aug 31. CareFusion Corp. is expected to generate earnings per share of $1.10 to $1.20 on a standalone basis. The S&#38;P 500 represents prices of the top 500 large-cap companies traded in the U.S. stock exchanges. It is one of the world’s most prestigious indices. Hundreds of billions of US dollars are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/cah-cardinals-spin-off-to-be-added-to-sp-500-index/13360/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TSL) Investing in Crude Oil: The Best Way to Play Oil’s Imminent Rebound</title>
		<link>http://www.stockbloghub.com/2009/03/10/tsl-investing-in-crude-oil-the-best-way-to-play-oil%e2%80%99s-imminent-rebound-3/4150</link>
		<comments>http://www.stockbloghub.com/2009/03/10/tsl-investing-in-crude-oil-the-best-way-to-play-oil%e2%80%99s-imminent-rebound-3/4150#comments</comments>
		<pubDate>Tue, 10 Mar 2009 18:08:01 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Semiconductor - Specialized]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Buffalo Wild Wings Inc.]]></category>
		<category><![CDATA[BWLD]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corp.]]></category>
		<category><![CDATA[Silver Wheaton Corp.]]></category>
		<category><![CDATA[SLW]]></category>
		<category><![CDATA[Trina Solar Ltd.]]></category>
		<category><![CDATA[TSL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4150</guid>
		<description><![CDATA[by Louis Basenese, Advisory Panelist Senior Analyst, The Oxford Club Billionaire investor George Soros and I don’t normally see eye to eye. He supports drug decriminalization, assisted suicide, America bashing… and a host of other off-the-reserve liberal causes. I don’t. I’m an old-school Reagan conservative. (Full disclosure &#8211; I’m so old school, I named my first born after the late President.) But here’s the thing. When it comes to investing, great political divides matter little. Because it’s not about getting our guy elected or unashamedly pushing a partisan agenda. Instead, business &#8211; and by extension, investing in businesses &#8211; is only about increasing profits, as Milton Friedman put it. And based on the latest SEC filing for Soros’ hedge fund, we both agree on the best way for investing in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/10/tsl-investing-in-crude-oil-the-best-way-to-play-oil%e2%80%99s-imminent-rebound-3/4150/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TSL) Investing in Crude Oil: The Best Way to Play Oil’s Imminent Rebound</title>
		<link>http://www.stockbloghub.com/2009/02/19/tsl-investing-in-crude-oil-the-best-way-to-play-oil%e2%80%99s-imminent-rebound/3194</link>
		<comments>http://www.stockbloghub.com/2009/02/19/tsl-investing-in-crude-oil-the-best-way-to-play-oil%e2%80%99s-imminent-rebound/3194#comments</comments>
		<pubDate>Fri, 20 Feb 2009 03:54:25 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Semiconductor - Specialized]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Buffalo Wild Wings Inc.]]></category>
		<category><![CDATA[BWLD]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corp.]]></category>
		<category><![CDATA[Silver Wheaton Corp.]]></category>
		<category><![CDATA[SLW]]></category>
		<category><![CDATA[Trina Solar Ltd.]]></category>
		<category><![CDATA[TSL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=3194</guid>
		<description><![CDATA[by Louis Basenese, Advisory Panelist Senior Analyst, The Oxford Club Billionaire investor George Soros and I don’t normally see eye to eye. He supports drug decriminalization, assisted suicide, America bashing… and a host of other off-the-reserve liberal causes. I don’t. I’m an old-school Reagan conservative. (Full disclosure &#8211; I’m so old school, I named my first born after the late President.) But here’s the thing. When it comes to investing, great political divides matter little. Because it’s not about getting our guy elected or unashamedly pushing a partisan agenda. Instead, business &#8211; and by extension, investing in businesses &#8211; is only about increasing profits, as Milton Friedman put it. And based on the latest SEC filing for Soros’ hedge fund, we both agree on the best way for investing in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/19/tsl-investing-in-crude-oil-the-best-way-to-play-oil%e2%80%99s-imminent-rebound/3194/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health, Inc.:  Stock of the Day</title>
		<link>http://www.stockbloghub.com/2009/02/17/cah-cardinal-health-inc-stock-of-the-day/2691</link>
		<comments>http://www.stockbloghub.com/2009/02/17/cah-cardinal-health-inc-stock-of-the-day/2691#comments</comments>
		<pubDate>Tue, 17 Feb 2009 22:36:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[W.W. Grainger]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2691</guid>
		<description><![CDATA[by David Fessler, Advisory Panelist, Investment U When we think of industrial suppliers, W.W. Grainger (NYSE:GWW) is one of the largest in the business. From nuts and bolts to janitorial supplies, it’s a good bet Grainger’s can supply it. The company consolidates parts, equipment and supplies from thousands of manufacturers and provides customers with one-stop shopping, both on its website and from its huge four inch thick catalog. Grainger’s has been bucking the trend and doing reasonably well during this business contraction. However it did acknowledge that business conditions in 2009 will be challenging, and its first quarter sales will be significantly lower than last quarter. As dismal as that sounds Grainger should be one of the first to benefit from the upswing when it comes. Motors, fans, bearings and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/17/cah-cardinal-health-inc-stock-of-the-day/2691/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Healthcare Stocks…Are They Truly Recession-Proof?</title>
		<link>http://www.stockbloghub.com/2009/01/22/sny-healthcare-stocks%e2%80%a6are-they-truly-recession-proof/2311</link>
		<comments>http://www.stockbloghub.com/2009/01/22/sny-healthcare-stocks%e2%80%a6are-they-truly-recession-proof/2311#comments</comments>
		<pubDate>Fri, 23 Jan 2009 01:05:32 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[DaVita Inc.]]></category>
		<category><![CDATA[DCAI]]></category>
		<category><![CDATA[Dialysis Corp. of America]]></category>
		<category><![CDATA[DVA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2311</guid>
		<description><![CDATA[Healthcare Stocks…Are They Truly Recession-Proof? This past weekend, I was up at my hunting and fishing club in northeast Pennsylvania enjoying some ice fishing. At our club at least, it’s a pleasant social activity with great food, wine and stories shared among the members and spouses.This year, it happened to fall on the coldest day of the winter, with the temperature dipping to 18 below. As you might expect this close to the inauguration, many folks are wondering what effect President Obama’s policies will have on the markets and investing. One of our members who’s a doctor, said: “Invest in healthcare stocks. It doesn’t matter who’s in the Whitehouse, and they’re recession-proof.” Are they? The answer depends on what area of healthcare you’re talking about. According to Health Affairs, an ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/22/sny-healthcare-stocks%e2%80%a6are-they-truly-recession-proof/2311/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

